Tharimmune Partners With Intract Pharma to Develop Oral Version of Infliximab for Autoimmune Diseases
Tharimmune Partners With Intract Pharma to Develop Oral Version of Infliximab for Autoimmune Diseases
Tharimmune與Intract Pharma合作開發口服版本的Infliximab用於自身免疫性疾病
Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it has entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody, infliximab. This strategic partnership aims to expand Tharimmune's therapeutic pipeline and reinforce its commitment to pioneering novel treatments for autoimmune diseases.
Tharimmune, Inc. (納斯達克:THAR)（"Tharimmune"或"公司"），一家臨床生物技術公司，正在開發一系列關於炎症和免疫學的治療候選藥物組合。今天宣佈，公司已與Intract Pharma達成最終協議，獨家許可INt-023/TH023，一種口服抗腫瘤壞死因子-α（TNF-α）單克隆抗體，英夫利昔單抗。這一戰略合作旨在擴大Tharimmune的治療管線，並強化其對自主治療自身免疫性疾病的承諾。
Under the terms of the agreement, Tharimmune licensed global development and commercialization rights (outside of South Korea) to Intract Pharma's Soteria and Phloral delivery platform along with...
根據協議的條款，Tharimmune在韓國以外的全球範圍...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間